| Market Cap | 111.82M | P/E | - | EPS this Y | -21.90% | Ern Qtrly Grth | - |
| Income | -12.36M | Forward P/E | -9.50 | EPS next Y | 7.70% | 50D Avg Chg | 7.00% |
| Sales | - | PEG | - | EPS past 5Y | - | 200D Avg Chg | -15.00% |
| Dividend | N/A | Price/Book | 4.17 | EPS next 5Y | - | 52W High Chg | -44.00% |
| Recommedations | 2.00 | Quick Ratio | 10.56 | Shares Outstanding | 32.18M | 52W Low Chg | 24.00% |
| Insider Own | 5.05% | ROA | -34.65% | Shares Float | 30.57M | Beta | 0.87 |
| Inst Own | 17.38% | ROE | -55.24% | Shares Shorted/Prior | 688.79K/701.76K | Price | 3.61 |
| Gross Margin | - | Profit Margin | - | Avg. Volume | 87,098 | Target Price | 8.50 |
| Oper. Margin | - | Earnings Date | - | Volume | 48,359 | Change | -0.55% |
Anixa Biosciences, Inc., a clinical-stage biotechnology company, focuses on the treatment and prevention of cancer. Its therapeutic portfolio consists of an ovarian cancer immunotherapy program being developed in collaboration with Moffitt Cancer Center, which uses a novel type of CAR- T, known as chimeric endocrine receptor T-cell (CER-T) technology. The company's vaccine portfolio includes a novel vaccine being developed in collaboration with Cleveland Clinic to prevent breast cancer primarily triple negative breast cancer (TNBC), the lethal form of the disease, as well as a vaccine to prevent ovarian cancer. Its vaccine technologies focus on immunizing against retired proteins that found to be expressed in certain forms of cancer. The company was formerly known as ITUS Corporation and changed its name to Anixa Biosciences, Inc. in October 2018. Anixa Biosciences, Inc. was incorporated in 1982 and is based in San Jose, California.
| EF Hutton | Buy | Sep 30, 24 |
| EF Hutton | Buy | Sep 24, 24 |
| HC Wainwright & Co. | Buy | Sep 17, 24 |
| EF Hutton | Buy | Sep 9, 24 |
| EF Hutton | Buy | Aug 7, 24 |
| HC Wainwright & Co. | Buy | Jul 24, 24 |
| HC Wainwright & Co. | Buy | Jun 10, 24 |
| HC Wainwright & Co. | Buy | Mar 21, 24 |
| HC Wainwright & Co. | Buy | Feb 13, 24 |
| Insider Trades | Relationship | Date | Transactions | Cost($) | #Shares | Value($) | #Share Own | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|
| Titterton Lewis H jr | Director Director | Oct 10 | Option | 2.575 | 16,000 | 41,200 | 823,028 | 10/11/23 |
| Titterton Lewis H jr | Director Director | Jul 27 | Option | 2.58 | 120,000 | 309,600 | 894,070 | 07/31/23 |
| KUMAR AMIT | Chief Executive Offi.. Chief Executive Officer | Jul 28 | Sell | 3.57 | 11,800 | 42,126 | 461,925 | 07/31/23 |
| KUMAR AMIT | Chief Executive Offi.. Chief Executive Officer | Jul 28 | Option | 2.58 | 40,000 | 103,200 | 502,100 | 07/31/23 |
| Catelani Michael | President, COO & CFO President, COO & CFO | Jul 20 | Buy | 3.64 | 5,500 | 20,020 | 26,655 | 07/21/23 |
| Titterton Lewis H jr | Director Director | Sep 29 | Option | 2.575 | 40,000 | 103,000 | 774,070 | 09/30/22 |
| Titterton Lewis H jr | Director Director | Jun 24 | Option | 2.58 | 46,000 | 118,680 | 1,034,070 | 06/28/22 |
| Titterton Lewis H jr | Director Director | Apr 26 | Buy | 2.79 | 10,000 | 27,900 | 988,070 | 04/27/22 |
| Catelani Michael | President President | Apr 21 | Buy | 2.66 | 5,500 | 14,630 | 18,135 | 04/22/22 |
| Catelani Michael | President President | Apr 20 | Buy | 2.53 | 2,509 | 6,348 | 12,635 | 04/21/22 |
| Titterton Lewis H jr | Director Director | Jan 12 | Buy | 3.28 | 5,000 | 16,400 | 978,070 | 01/13/22 |
| Titterton Lewis H jr | Director Director | Jan 11 | Buy | 3.20 | 2,000 | 6,400 | 973,070 | 01/12/22 |
| Titterton Lewis H jr | Director Director | Jan 10 | Buy | 3.08 | 6,000 | 18,480 | 971,070 | 01/11/22 |
| Titterton Lewis H jr | Director Director | Jan 07 | Buy | 3.08 | 11,000 | 33,880 | 965,070 | 01/10/22 |
| KUMAR AMIT | Chief Executive Offi.. Chief Executive Officer | Jan 07 | Buy | 3.00 | 20,000 | 60,000 | 314,000 | 01/07/22 |